Statistics

Total Visits

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati66

Select a period of time:

Number of views in the range

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati15

Views

Views
September 20253
October 20250
November 20256
December 20253
January 20261
February 20260
March 20262
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil5
United States3
Ecuador2
Argentina2
Germany1
Panama1
South Africa1
 

Top cities views

Views
Guayaquil2
Cape Town1
Dallas1
Fazenda Rio Grande1
Frankfurt am Main1
Morón1
Nogoyá1
Panama City1
Rio de Janeiro1
San Jose1